Literature DB >> 11376581

The impact of diabetes on arterial reconstructions for multilevel arterial occlusive disease.

P L Faries1, F W LoGerfo, S C Hook, M C Pulling, C M Akbari, D R Campbell, F B Pomposelli.   

Abstract

PURPOSE: Critical limb ischemia due to multilevel arterial occlusive disease often may be treated with an inflow procedure alone; however, a subset patients require a subsequent infrainguinal revascularization for persistence of their symptoms. As diabetic patients typically exhibit a pattern of extensive distal arterial disease, we sought to determine if the presence of diabetes mellitus altered the need for an outflow procedure after inflow bypass.
METHODS: A total of 504 patients undergoing inflow bypass for occlusive disease and lower extremity ischemia between 1990 and 1998 were entered prospectively into a computerized vascular registry. Inflow bypass procedures performed were as follows: aortofemoral (370; 73%), axillofemoral (56; 11%), femorofemoral (81; 16%). Of these patients, 79 required subsequent outflow bypass for unresolved ischemic symptoms. Multiple logistic regression analysis was used to analyze the effects of diabetes and multiple other risk factors on the need for an additional outflow procedure.
RESULTS: The indications for surgery were limb salvage (78%) and disabling claudication (22%). Overall morbidity was 17.7% (hematoma, 3.8%; wound infection, 2.5%; graft occlusion, 1.3%; myocardial infarction, 2.5%; acute renal failure,1.3%; pulmonary failure, 2.5%; pneumonia, 3.8%). Overall mortality was 0%. Diabetic patients comprised a greater proportion of the total number of patients requiring inflow bypass (301 of 504) as well as a greater proportion of patients requiring inflow and outflow procedures (47 of 79). Diabetes was determined not to be an independent risk factor for the need for multiple revascularization procedures by multiple logistic regression analysis (P >0.10).
CONCLUSION: Although patients with diabetes are predisposed to the development of distal arterial occlusive disease, in this study the subgroup of diabetic patients who present with aortoiliac occlusive disease were no more likely than patients without diabetes to require multiple levels of revascularization. These findings provide little rationale for simultaneous inflow and outflow procedures based on the presence of diabetes alone.

Entities:  

Mesh:

Year:  2001        PMID: 11376581     DOI: 10.1016/s0002-9610(01)00551-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Extra-anatomical bypass grafting--a single surgeon's experience.

Authors:  N D Appleton; D Bosanquet; G Morris-Stiff; H Ahmed; P Sanjay; M H Lewis
Journal:  Ann R Coll Surg Engl       Date:  2010-06-01       Impact factor: 1.891

Review 2.  Peripheral arterial disease: clinical assessment and indications for revascularization in the patient with diabetes.

Authors:  Bart E Muhs; Paul Gagne; Peter Sheehan
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

3.  Pilot study of contrast-free MRI reveals significantly impaired calf skeletal muscle perfusion in diabetes with incompressible peripheral arteries.

Authors:  Jie Zheng; Ran Li; Mohamed A Zayed; Yan Yan; Hongyu An; Mary K Hastings
Journal:  Vasc Med       Date:  2021-03-22       Impact factor: 4.739

4.  CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα.

Authors:  Mohamed A Zayed; Xiaohua Jin; Chao Yang; Larisa Belaygorod; Connor Engel; Kshitij Desai; Nikolai Harroun; Omar Saffaf; Bruce W Patterson; Fong-Fu Hsu; Clay F Semenkovich
Journal:  Diabetes       Date:  2020-11-19       Impact factor: 9.461

5.  Open and Endovascular Treatment of Trans-Atlantic Inter-Society Consensus II D Aortoiliac Occlusive Lesions: What Determines the Rate of Restenosis?

Authors:  Chen-Yang Shen; Yun-Feng Liu; Qing-Le Li; Yong-Bao Zhang; Yang Jiao; Miltiadis E Krokidis; Xiao-Ming Zhang
Journal:  Chin Med J (Engl)       Date:  2015-11-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.